Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Forte Biosciences, Inc. (FBRX) had Consolidated Net Income/Loss of $-35.48M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-35.48M |
|
-- |
|
-- |
|
$36.60M |
|
$-36.60M |
|
$1.12M |
|
$-35.48M |
|
$-35.48M |
|
$-35.48M |
|
$-35.48M |
|
|
Consolidated Net Income/Loss |
$-35.48M |
$-35.48M |
|
$-36.60M |
|
$-36.56M |
|
2.92M |
|
2.92M |
|
$-12.17 |
|
$-12.17 |
|
| Balance Sheet Financials | |
$61.35M |
|
$0.08M |
|
$0.21M |
|
$61.56M |
|
$9.08M |
|
-- |
|
-- |
|
$9.08M |
|
$52.48M |
|
$52.48M |
|
$52.48M |
|
6.39M |
|
| Cash Flow Statement Financials | |
$-30.75M |
|
$-35.99M |
|
$51.86M |
|
$37.12M |
|
$22.24M |
|
$-14.88M |
|
$3.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-30.78M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-67.60% |
|
-67.60% |
|
-57.63% |
|
-67.60% |
|
$8.21 |
|
$-10.56 |
|
$-10.54 |
|